Antibiotic—Lysobacter enzymogenes proteases combination as a novel virulence attenuating therapy
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0282705 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Ghadeer A R Y Suaifan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, School of Pharmacy, The University of Jordan, Amman, Jordan. Hauptthemen laut MEDLINE: Methicillin-Resistant Staphylococcus aureus. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deanship of Scientific Research, University of Jordan, Hamdi mango centre for scientific research.
Abstract (Originalsprache)
Minimizing antibiotic resistance is a key motivation strategy in designing and developing new and combination therapy. In this study, a combination of the antibiotics (cefixime, levofloxacin and gentamicin) with Lysobacter enzymogenes ( L . enzymogenes ) bioactive proteases present in the cell- free supernatant (CFS) have been investigated against the Gram-positive methicillin-sensitive Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus aureus (MRSA) and the Gram-negative Escherichia coli ( E . coli O157:H7). Results indicated that L . enzymogenes CFS had maximum proteolytic activity after 11 days of incubation and higher growth inhibitory properties against MSSA and MRSA compared to E . coli (O157:H7). The combination of L . enzymogenes CFS with cefixime, gentamicin and levofloxacin at sub-MIC levels, has potentiated their bacterial inhibition capacity. Interestingly, combining cefixime with L . enzymogenes CFS restored its antibacterial activity against MRSA. The MTT assay revealed that L . enzymogenes CFS has no significant reduction in human normal skin fibroblast (CCD-1064SK) cell viability. In conclusion, L . enzymogenes bioactive proteases are natural potentiators for antimicrobials with different bacterial targets including cefixime, gentamicin and levofloxacin representing the beginning of a modern and efficient era in the battle against multidrug-resistant pathogens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, School of Pharmacy, The University of Jordan, Amman, Jordan.
- Department of Pharmaceutical Chemistry and Pharmacognosy, School of Pharmacy, Applied Science Private University, Jordan, Amman.
- School of Medicine, The University of Jordan, Amman, Jordan.
- Department of Pharmaceutics and Pharmaceutical Biotechnology, School of Pharmacy, The University of Jordan, Amman, Jordan.
ORCID-Profile: Ghadeer A R Y Suaifan, Mayadah B Shehadeh, Rula M Darwish
Förderung
- Deanship of Scientific Research, University of Jordan
- Hamdi mango centre for scientific research
Zitieren
APA
Suaifan, G. A. R. Y., Abdel Rahman, D. M. A., Abu-Odeh, A. M., Abu Jbara, F., Shehadeh, M. B., & Darwish, R. M. (2023). Antibiotic—Lysobacter enzymogenes proteases combination as a novel virulence attenuating therapy. PLOS ONE. https://doi.org/10.1371/journal.pone.0282705
Vancouver
Suaifan GARY, Abdel Rahman DMA, Abu-Odeh AM, Abu Jbara F, Shehadeh MB, Darwish RM. Antibiotic—Lysobacter enzymogenes proteases combination as a novel virulence attenuating therapy. PLOS ONE. 2023. doi:10.1371/journal.pone.0282705
BibTeX
@article{Suaifan2023,
author = {Suaifan, Ghadeer A R Y and Abdel Rahman, Diana M A and Abu-Odeh, Ala' M and Abu Jbara, Fahid and Shehadeh, Mayadah B and Darwish, Rula M},
title = {Antibiotic—Lysobacter enzymogenes proteases combination as a novel virulence attenuating therapy},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0282705}
}
EUVIMED